Trial Results

NTI’s two clinical trial results are in - Treatment success for BOTH Autism AND for Rett Syndrome

Next Investors Apr 17, 2024

Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.

First on the ASX - BOD announces successful outcome for insomnia clinical trial

Wise-Owl Sep 06, 2023

Our investment, BOD Science (ASX: BOD), has successfully demonstrated the statistical efficacy of its 100mg CBD product for treating insomnia in a Phase IIb study. This milestone puts BOD on track to be the first Australian company to offer a CBD-based insomnia treatment over-the-counter.